Article
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Cancer research - 1 Feb 2010
Sos Martin L, Rode Haridas B, Heynck Stefanie, Peifer Martin, Fischer Florian, Klüter Sabine, Pawar Vijaykumar G, Reuter Cecile, Heuckmann Johannes M, Weiss Jonathan, Ruddigkeit Lars, Rabiller Matthias, Koker Mirjam, Simard Jeffrey R, Getlik Matthäus, Yuza Yuki, Chen Tzu-Hsiu, Greulich Heidi, Thomas Roman K, Rauh Daniel
Abstract excerpt
Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small molecules to improve progression-free survival of patients with EGFR-mutated lung cancers. Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clinical activity in patients with T790M-mutant tumors. In this study, we systematically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.